Yaron Breski

Previously, he served as a senior executive of business development at Rosetta Genomics, a micro-RNA based, biotechnology company focusing on personalized medicine and cancer diagnostics. In his role, he led the company's business development activities in the United States and Rest-of-World and was responsible for all of the company's in-licensing and out-licensing activities. During his time at Rosetta he has worked closely with the business development groups of most of the big pharmaceutical, biotechnology, and diagnostic companies, as well as the technology and licensing groups in many of the leading oncology research centers in the US.

Before joining Rosetta Mr. Breski was part of the US Strategic Planning group at Novartis Pharmaceutical Corp. where he focused on value chain analysis of US pharmaceutical distribution chain and prior to that worked within Booz Allen Hamilton's Healthcare consulting group in New York, focusing on post-merger integration strategies.

Before arriving at the United States Mr. Breski was working with Israel's Ministry of Science and Technology to streamline and improve Israel's academy-industry R&D commercialization pipeline.